1-Phthalidyl-5-fluorouracil (also known as **5-FUrd**) is a prodrug of the chemotherapy drug **5-fluorouracil (5-FU)**.
Here's a breakdown of its importance:
**What it is:**
* **Prodrug:** A prodrug is a compound that is inactive when administered but is converted into an active drug by the body.
* **5-FUrd** is a derivative of 5-FU where a phthalidyl group is attached. This modification helps 5-FUrd to be absorbed better and have a longer duration of action compared to 5-FU.
**Why it is important for research:**
* **Enhanced efficacy:** 5-FUrd is more effective in treating cancer than 5-FU, especially in certain cancers like colorectal cancer. This makes it a valuable tool for researchers investigating new cancer treatments.
* **Improved pharmacokinetic profile:** 5-FUrd exhibits a better pharmacokinetic profile (how the drug is absorbed, distributed, metabolized, and excreted) compared to 5-FU, meaning it stays in the body longer and reaches higher concentrations in tumor tissues.
* **Lower side effects:** While 5-FU is associated with side effects like nausea, vomiting, and diarrhea, 5-FUrd is generally tolerated better.
* **Potential for targeted drug delivery:** 5-FUrd has been explored for targeted drug delivery systems. This involves attaching it to specific molecules that can direct it to cancer cells, potentially increasing efficacy and minimizing damage to healthy tissues.
**Research applications:**
* **Cancer treatment:** 5-FUrd is being investigated in clinical trials for various cancers, including colorectal, breast, and pancreatic cancer.
* **Drug development:** 5-FUrd serves as a basis for developing novel anticancer agents by modifying the phthalidyl group or exploring new prodrug strategies.
* **Pharmacokinetic studies:** 5-FUrd is a valuable model compound for understanding prodrug metabolism and absorption.
**Overall, 1-Phthalidyl-5-fluorouracil is a promising anticancer agent with several advantages over its parent drug, 5-fluorouracil. Its improved efficacy, pharmacokinetic profile, and potential for targeted drug delivery make it an important area of research for developing new and better cancer treatments.**
1-phthalidyl-5-fluorouracil: prodrug of 5-fluorouracil; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 128467 |
| CHEMBL ID | 21040 |
| SCHEMBL ID | 4886494 |
| MeSH ID | M0128928 |
| Synonym |
|---|
| 1-(1,3-dihydro-3-oxo-1-isobenzofuranyl)-5-fluoro-2,4(1h,3h)-pyrimidinedione |
| n(sub 1)-phthalidyl-5-fluorouracil |
| 2,4(1h,3h)-pyrimidinedione, 1-(1,3-dihydro-3-oxo-1-isobenzofuranyl)-5-fluoro- |
| 1-phthalidyl-5-fluorouracil |
| 1-pfu |
| CHEMBL21040 |
| 81820-68-0 |
| nf1jn84r8k , |
| unii-nf1jn84r8k |
| SCHEMBL4886494 |
| 1-phthalidyl-5-fluorouracil, (+/-)- |
| n1-phthalidyl-5-fluorouracil |
| n-phthalidyl-5-fluorouracil |
| Q27284839 |
| 5-fluoro-4-hydroxy-1-(3-oxo-1,3-dihydro-2-benzofuran-1-yl)pyrimidin-2(1h)-one |
| DTXSID901002250 |
| 5-fluoro-1-(3-oxo-1,3-dihydroisobenzofuran-1-yl)pyrimidine-2,4(1h,3h)-dione |
| PD160058 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The preclinical pharmacokinetic studies revealed a steep increase and rapid decrease of 590-S and activated 5-FU in the blood compared with those of other fluorinated pyrimidines." | ( [Pharmacokinetic studies of a new fluorinated pyrimidine, 590-S (PH-FU), in human patients]. , 1986) | 0.27 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID136585 | In vivo antitumor activity against MH 134 cell line in female BDF1 mice after oral administered dose of 25 mg/kg | 1982 | Journal of medicinal chemistry, Oct, Volume: 25, Issue:10 | Studies on the synthesis of chemotherapeutics. 12. Synthesis and antitumor activity of N-phthalidyl-5-fluorouracil derivatives. |
| AID136584 | In vivo antitumor activity against MH 134 cell line in female BDF1 mice after oral administered dose of 200 mg/kg | 1982 | Journal of medicinal chemistry, Oct, Volume: 25, Issue:10 | Studies on the synthesis of chemotherapeutics. 12. Synthesis and antitumor activity of N-phthalidyl-5-fluorouracil derivatives. |
| AID136592 | In vivo antitumor activity against P-388 Leukemia cell line in female BDF1 mice after oral administered dose of 200 mg/kg | 1982 | Journal of medicinal chemistry, Oct, Volume: 25, Issue:10 | Studies on the synthesis of chemotherapeutics. 12. Synthesis and antitumor activity of N-phthalidyl-5-fluorouracil derivatives. |
| AID136589 | In vivo antitumor activity against Meth A cell line in female BDF1 mice after oral administered dose of 200 mg/kg; death | 1982 | Journal of medicinal chemistry, Oct, Volume: 25, Issue:10 | Studies on the synthesis of chemotherapeutics. 12. Synthesis and antitumor activity of N-phthalidyl-5-fluorouracil derivatives. |
| AID136587 | In vivo antitumor activity against Meth A cell line in female BDF1 mice after oral administered dose of 150 mg/kg | 1982 | Journal of medicinal chemistry, Oct, Volume: 25, Issue:10 | Studies on the synthesis of chemotherapeutics. 12. Synthesis and antitumor activity of N-phthalidyl-5-fluorouracil derivatives. |
| AID136583 | In vivo antitumor activity against MH 134 cell line in female BDF1 mice after oral administered dose of 150 mg/kg | 1982 | Journal of medicinal chemistry, Oct, Volume: 25, Issue:10 | Studies on the synthesis of chemotherapeutics. 12. Synthesis and antitumor activity of N-phthalidyl-5-fluorouracil derivatives. |
| AID136593 | In vivo antitumor activity against P-388 Leukemia cell line in female BDF1 mice after oral administered dose of 25 mg/kg | 1982 | Journal of medicinal chemistry, Oct, Volume: 25, Issue:10 | Studies on the synthesis of chemotherapeutics. 12. Synthesis and antitumor activity of N-phthalidyl-5-fluorouracil derivatives. |
| AID136594 | In vivo antitumor activity against P-388 Leukemia cell line in female BDF1 mice after oral administered dose of 50 mg/kg | 1982 | Journal of medicinal chemistry, Oct, Volume: 25, Issue:10 | Studies on the synthesis of chemotherapeutics. 12. Synthesis and antitumor activity of N-phthalidyl-5-fluorouracil derivatives. |
| AID136590 | In vivo antitumor activity against Meth A cell line in female BDF1 mice after oral administered dose of 50 mg/kg | 1982 | Journal of medicinal chemistry, Oct, Volume: 25, Issue:10 | Studies on the synthesis of chemotherapeutics. 12. Synthesis and antitumor activity of N-phthalidyl-5-fluorouracil derivatives. |
| AID136586 | In vivo antitumor activity against MH 134 cell line in female BDF1 mice after oral administered dose of 50 mg/kg | 1982 | Journal of medicinal chemistry, Oct, Volume: 25, Issue:10 | Studies on the synthesis of chemotherapeutics. 12. Synthesis and antitumor activity of N-phthalidyl-5-fluorouracil derivatives. |
| AID136588 | In vivo antitumor activity against Meth A cell line in female BDF1 mice after oral administered dose of 200 mg/kg | 1982 | Journal of medicinal chemistry, Oct, Volume: 25, Issue:10 | Studies on the synthesis of chemotherapeutics. 12. Synthesis and antitumor activity of N-phthalidyl-5-fluorouracil derivatives. |
| AID136591 | In vivo antitumor activity against P-388 Leukemia cell line in female BDF1 mice after oral administered dose of 100 mg/kg | 1982 | Journal of medicinal chemistry, Oct, Volume: 25, Issue:10 | Studies on the synthesis of chemotherapeutics. 12. Synthesis and antitumor activity of N-phthalidyl-5-fluorouracil derivatives. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 9 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.15) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||